Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Results in The New England Journal of Medicine confirm Novartis drug Femara is superior to tamoxifen after breast cancer surgery
Results in The New England Journal of Medicine confirm Novartis drug Femara is superior to tamoxifen after breast cancer surgery
Results in The New England Journal of Medicine confirm Novartis drug Femara is superior to tamoxifen after breast cancer surgery
Submitted by
admin
on August 20, 2009 - 10:58am
Source:
Fierce Biotech
News Tags:
Novartis
New England Journal of Medicine
breast cancer
Femara
tamoxifen
Headline:
Results in The New England Journal of Medicine confirm Novartis drug Femara is superior to tamoxifen after breast cancer surgery
Do Not Allow Advertisers to Use My Personal information
